Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and share ownership changes rather than corporate financial performance.
Material Changes
On September 30, 2013, Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.74 per share and notional American Depositary Shares (ADSs) at $50.53 per ADS. These allocations covered the service period from July 1, 2013, to September 30, 2013. The Company and Directors were informed of these allocations on October 1, 2013.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Non-Executive Directors received notional share allocations for the Q3 2013 service period.
- The allocation price was £15.74 per Ordinary Share and $50.53 per ADS.
- Allocations were distributed to 12 Non-Executive Directors, including Sir Christopher Gent, Professor Sir Roy Anderson, and Judy Lewent.
- This filing does not contain financial results or strategic updates for the company.